Joint Scientific Consultations (JSC)

Joint Scientific Consultations (JSC)

2nd Open Call for parallel EMA/EUnetHTA 21 Joint Scientific Consultations (JSCs) closed

The second Open Call for applications from the pharmaceutical industry for Joint Scientific Consultations (JSCs) closed on 31 August, 2022.

The EUnetHTA 21 Committee for Scientific Consistency and Quality (CSCQ) JSC is currently reviewing the applications received. The applicants will be informed of the CSCQ JSC decision within 15 working days after the Open Call has been closed.

A maximum of five JSCs will be selected in this second Open Call.

2nd Open Call – EUnetHTA 21 JSC

Publish online

6.6.2022

Open Call open

6.6. – 31.8.2022

Selection of products

12.9.2022

Information sent to applicants

14.9.2022

Start of JSC (5 additional JSC foreseen)

1.11.2022

__________

Parallel EMA/EUnetHTA 21 Joint Scientific Consultation (JSC)

Parallel EMA/EUnetHTA 21 Joint Scientific Consultations (JSCs) provide a non-binding scientific advice, before the start of pivotal clinical trials (after feasibility / proof of concept study), in order to improve the quality and appropriateness of the data produced by the HTD in view of future HTA assessment / re-assessment.

Parallel EMA/EUnetHTA 21 JSCs should enable an exchange between the applicant and HTA agencies and regulators (EMA) at an early stage in the development process in order to allow the integration of the different requirements across multiple European Member States (e.g. choice of comparators, relevant outcomes, quality of life, patient groups) in the study design (pivotal trials & post-launch evidence generation (PLEG)) and the economic evidence generation plan. However, when consensus is not possible, the views of participating HTA bodies will be made known to the applicant.

EUnetHTA 21 (2021 – 2023) offers at least 6, up to a maximum of 8 JSCs (formerly referred to as Early Dialogues) for medicinal products. Prospective and timely advice may allow the applicant to integrate specific HTA and regulatory needs into the development plan and, therefore, fulfil the evidence requirements of both regulators and HTA bodies at the same time.

The EUnetHTA 21 partners will continue to work with the EMA to improve the consultation processes and their coordination in order to meet the demand for consultations while ensuring the best scientific quality. Detailed information regarding parallel EMA/EUnetTHA 21 JSC is available on the Parallel EMA/EUnetHTA 21 JSC page of this website.

All EMA/EUnetHTA 21 JSCs are supported by the EUnetHTA 21 JSC Secretariat (EUnetHTA21-JSC@g-ba.de), thereby benefiting from HTA scientific and administrative coordination, consolidated HTA comments, a concerted effort to find agreement among the CSCQ JSC regarding specific issues as well as a consolidated document containing EUnetHTA 21’s Final Written Recommendations. Opportunities for closed discussion amongst HTA bodies, and with regulators with mutual understanding, are maximised

Due to the tender specifications, the number of products to be selected for JSCs in EUnetHTA 21 is limited. As the number of applicants is expected to exceed the number of slots, a selection of products will be necessary. A prerequisite for a JSC is that the clinical studies (phase II/ III) and clinical investigations are still in the planning stage. Furthermore, EUnetHTA 21 will apply the same selection criteria as defined in the EU HTA regulation. The criteria for selecting from eligible JSC requests for medicinal products are:

  1. Unmet medical needs (no treatment or only unsatisfactory treatment available);
  2. First in class;
  3. Potential impact on patients, public health, or healthcare systems;
  4. Significant cross-border dimension;
  5. Major Union-wide added value; or
  6. Union clinical research priorities

Oncology products and/or ATMPs and indications for which there is no established guidance for clinical development (i.e. in absence of recent HTA evaluation in similar indication) are also given preferred consideration.

The specification of the selection criteria, their operationalisation and applicability will be further developed in the course of EUnetHTA 21.

More information can also be found in the Frequently Asked Questions (FAQ) section of the EUnetHTA 21 JSC website.

In all cases, the submitted applications must comply with the selection criteria listed above. The members of the Committee for Scientific Consistency and Quality (CSCQ) JSC will review the applications. 

The Committee for Scientific Consistency and Quality (CSCQ) JSC

Within the framework of EUnetHTA 21, the JSC are carried out by the members of the CSCQ JSC, which are: AEMPS (Spain), AIFA (Italy), G-BA (Germany), HAS (France), INFARMED (Portugal), KCE (Belgium), NCPE (Ireland), NIPN (Hungary), NOMA (Norway), TLV (Sweden) and ZIN (The Netherlands). EUnetHTA 21 offers JSCs on clinical and economic evidence generation for pharmaceutical products. EUnetHTA 21 is a one-stop-shop for the involvement of HTA bodies in JSCs with the primary contact point being the EUnetHTA 21 JSC Secretariat (EUnetHTA21-JSC@g-ba.de).

General Objectives of parallel EMA/EUnetHTA 21 JSCs

EUnetHTA 21 strives to support generation of good quality evidence for proper HTA. To this end, our objectives include:

  • Support developers of medical technologies by providing a collaborative approach among a wide-range of European HTA bodies to provide consolidated advice on their product evidence generation plans while also maintaining individual HTA bodies positions where needed. 
  • Supply and incorporate patient and clinical expert contributions in the final recommendations provided by HTA bodies.
  • Optimize the interaction with regulators for medicinal products, through parallel EMA/EUnetHTA 21 JSCs.


General Aspects and Practical Considerations

Parallel EMA/EUnetHTA 21 JSCs remain confidential and are non-binding for either of the parties involved. Secure systems are used for exchange of documents between the applicant and the EUnetHTA 21 JSC Secretariat, as well as between the EUnetHTA 21 JSC Secretariat and the participating HTA bodies.

All participants in a JSCs (including patients/patient representatives and healthcare professionals) are required to complete a Declaration of Interest (DOI) and Confidentiality Agreements form. These documents together with the DOI handling procedures are available here.

Applicants are advised to review all information available on this website prior to submitting a request. All requests must be made during EUnetHTA 21’s Open Call periods for JSC.

Further information regarding parallel EMA/EUnetHTA 21 JSC, including guidance documents and templates, can be found in the corresponding sections of the EUnetHTA 21 JSC website. Any inquiries regarding the JSCs should be directed to the EUnetHTA 21 JSC Secretariat (EUnetHTA21-JSC@g-ba.de).

Note: For JA3 Early Dialogues, please go to this link.